• HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study

    Source: Nasdaq GlobeNewswire / 19 Jul 2023 20:00:00   America/New_York

    N/A
Share on,